Drugs / MAM01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06408857 | Mar 2025 → May 2026 | — | Gates Medical Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT05891236 | Aug 2023 → Dec 2024 | malaria | Gates Medical Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05891236 ↗ |
| Modality | Monoclonal antibody | “This is a First-in-Human (FiH), randomized, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP).” NCT05891236 ↗ |
| Route | Intravenous | “1.5 mg/kg MAM01 will be administered via IV route.” NCT05891236 ↗ |